子宫内膜腺癌C-erbB-2COX-2过度表达的相关性分析

Expression of C-erbB-2 and COX-2 and Their Relationship in Endometrial Adenocarcinoma

目的:研究C-erbB-2、COX-2在子宫内膜增生性病变和子宫内膜腺癌中的表达特点及其相关性。方法:应用免疫组织化学S-P法检测了20例正常增生期子宫内膜、23例单纯性子宫内膜增生、21例复杂性子宫内膜增生、43例非典型性子宫内膜增生、25例子宫内膜腺癌中C-erbB-2、COX-2的表达。结果:C-erbB-2和COX-2在各实验组中的阳性表达率:单纯性增生组为4.5%和9.1%,复杂性增生组为4.8%和14.3%,低级别非典型增生组为30.0%和25.0%,高级别非典型增生组为60.9%和52.4%,腺癌组为92.0%和91.7%;C-erbB-2、COX-2在各实验组间差异均有显著性(P=0.000)。C-erbB-2与COX-2在各组的表达水平呈显著正相关关系(P<0.01)。结论:C-erbB-2、COX-2可能在子宫内膜癌的发生发展中发挥重要的协同作用,两者联合检测对子宫内膜腺癌及癌前病变的鉴别诊断有较高的诊断价值。

Objective： To detect the expression of C-erbB-2 and COX-2 in hyperplastic and malignant endometrial epithelial tissues and to explore the relationship between the expression levels of these two proteins. Methods： Immunohistochemistry （S-P method） was used to detect the expression of C-erbB-2 and COX-2 in 20 cases of normal proliferative endometrium, 23 cases of simple endometrial hyperplasia, 21 cases of complex endometrial hyperplasia, 43 cases of atypical endometrial hyperplasia, and 25 cases of endometrial adenocarcinoma. Results： The positive expression rates of C-erbB-2 and COX-2 were 4.5% and 9.1% in simple endometrial hyperplasia, 4.8% and 14.3% in complex endometrial hyperplasia, 30.0% and 25.0% in low-grade atypical endometrial hyperplasia, 60.9% and 52.4% in high-grade atypical endometrial hyperplasia, and 92.0% and 91.7% in endometrial adenocarcinoma, respectively. There was a significant difference in the expression of C-erbB-2 and COX-2 between hyperplastic and malignant endometrial epithelial tissue samples （P=0.000）. A positive correlation was found between C-erbB-2 and COX-2 expression （P〈0.01）. Conclusion： An abnormal expression of C-erbB-2 and COX-2 may contribute to the pathogenesis and development of endometrial carcinoma. The combined detection of C-erbB-2 and COX-2 proteins may be valuable in distinguishing endometrial adenocarcinoma from endometrial hyperplastic lesions.